ReviewEndocrine2005
Classification and pathology of pituitary tumors.
Review in Endocrine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 104 citations in OpenAlex.
- Perioperative cortisol can predict hypothalamus-pituitary-adrenal status in clinically non-functioning pituitary adenomas.Journal of endocrinological investigation · 2009Trial
- Transcription factor-based classification of pituitary adenomas / PitNETs: a comparative analysis and clinical implications across WHO 2004, 2017 and 2022 in 921 cases.Acta neuropathologica communications · 2025Article
- Clinico-radio-pathological predictors of outcomes in patients with acromegaly undergoing endoscopic transsphenoidal surgery.Surgical neurology international · 2024Article
- Natural history of pituitary carcinoma with metastasis to the cervical spine: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Classification of Brain Tumor from Magnetic Resonance Imaging Using Vision Transformers Ensembling.Current oncology (Toronto, Ont.) · 2022Article
- A novel diagnostic method for pituitary adenoma based on magnetic resonance imaging using a convolutional neural network.Pituitary · 2020Article
- A Population-Level Analysis of Pituitary Carcinoma from the National Cancer Database.Journal of neurological surgery. Part B, Skull base · 2020Article
- Case Report of a Pituitary Metastasis from Lung Adenocarcinoma Masquerading as Pituitary Adenoma.Journal of the ASEAN Federation of Endocrine Societies · 2020Article
- Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.Frontiers in endocrinology · 2020Review
- Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?Journal of neuro-oncology · 2018Article
- Silent somatotroph pituitary adenomas: an update.Pituitary · 2018Review
- PKCδ reveals a tumor promoter function by promoting cell proliferation and migration in somatotropinomas.International journal of clinical and experimental pathology · 2018Article
- Article
- Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement.Pituitary · 2017Article
- Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Expression and Clinical Significance of miR-26a and Pleomorphic Adenoma Gene 1 (PLAG1) in Invasive Pituitary Adenoma.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.Pituitary · 2016Article
- Predictive value of PWI for blood supply and T1-spin echo MRI for consistency of pituitary adenoma.Neuroradiology · 2016Article
- Article
- Visual loss due to optic chiasm and retrochiasmal visual pathway lesions.Continuum (Minneapolis, Minn.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas originating in adenohypophysial cells represent the most common neoplasms of the sella turcica. The pathologist's goal is the optimal diagnosis and classification of pituitary adenomas. Lack of clinicopathological correlations in the past classification of pituitary adenomas, which was based on the tinctorial properties of adenoma cells, limited the importance of histological diagnosis. Morphologic separation of pituitary cells by electron microscopy provided fundamental knowledge to classify pituitary adenomas. Immunohistochemistry represents the gold standard of the current classification. Combined morphologic and immunohistochemical diagnostic approaches resulted in the clinicopathologic classification of pituitary adenomas. The WHO classification of 2004 is based on morphologic features and takes into consideration findings from imaging procedures and clinical symptoms. Morphologic characterization of pituitary tumors and correlation of the hormone product with hormone secretion provides the clinician with useful information. In addition, the utility of tumor markers offers objective information in managing the patient and predicting responses to specific treatment. The Ki-67 labeling index (LI) is widely used for it correlates with invasiveness and probably prognosis. Adenomas showing increased ( >3%) LI and extensive p53 immunoreactivity should be termed "atypical adenomas" suggesting aggressive potential or malignant transformation. Morphologic separation of adenoma from carcinoma is not feasible. The term pituitary carcinoma should be exclusively applied when cerebrospinal and/or systemic metastases are definite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.